Attovia Therapeutics, Inc. (ATTO)
Attovia Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Carlos, CA, US. The stock last traded at $17.78, down 2.15% on the session, giving a market capitalisation of $765.1M. On trailing twelve-month figures it carries a trailing P/E of -19.12, a net margin of -8742.9%. Its beta of 0.00 implies it has historically moved less than the broad market.
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.